Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of TD-9855 for symptomatic neurogenic orthostatic hypotension in primary autonomic failure
MOH_2019-06-19_006016Phase 3Recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Neurogenic Orthostatic Hypotension (nOH) comparing TD-9855 10 mg with Placebo (2 arms). Primary endpoint: Change from baseline in Orthostatic Hypotension Symptom Assessment question 1 score at week 4. Started Apr 2019; status: recruiting.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on MOH_2019-06-19_006016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-19_006016.